Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × Disease × Clear all

Phase

Phase NA 51 Phase 2 19 Phase 3 12 Phase 1 6 Phase 1/2 4 Phase EARLY_PHASE1 3 Phase 4 1 Phase 2/3 1

Status

Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 33 Breast Neoplasms 32 Prostatic Neoplasms 27 Leukemia, Myeloid, Acute 21 Carcinoma, Non-Small-Cell Lung 19 Colorectal Neoplasms 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Neoplasm Metastasis 14 Polycystic Ovary Syndrome 11 Multiple Myeloma 11 Lung Neoplasms 11 Carcinoma, Hepatocellular 11 Stomach Neoplasms 10 Urinary Bladder Neoplasms 8 Pancreatic Neoplasms 8 Motor Activity 8 Lymphoma 8 Recurrence 7 Myelodysplastic Syndromes 7 Liver Neoplasms 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Leukemia 7 Head and Neck Neoplasms 7 Esophageal Neoplasms 7 Brain Neoplasms 7 Pain 6 Ovarian Neoplasms 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Hematologic Neoplasms 6

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02981368 2021-08-09

OSPREY

Progenics Pharmaceuticals, Inc.

Phase 2/3 Completed

385 enrolled 20 charts

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡